21 sep: DSV/Jyske: Sænker anbefaling til "reducer" efter kursridt
21 sep: Danmark/Økonomer: Beskæftigelsesnedgang giver ingen grund til pan..
21-09-2017 10:13:32

Bavarian Nordic Provides Update on its Universal RSV Vaccine

Relateret indhold
24 sep - 
Mandagens aktier: Ambu og Danske faldt i nervøst og afv..
24 sep - 
Aktier/middag: Ambu og Danske ryger til bunds i nervøst..
21 sep - 
Aktier/åbning: Danske Bank skraber bunden i positivt el..
Relateret debat
24 sep - 
tak
24 sep - 
https://www.helsingordagblad.dk/2018/03/24/ny-fabrik-go..
24 sep - 
De har sagt det mange gange - senest under præsentation..

  • Preliminary 6 Month Phase 2 Data continue to Demonstrate a Broad and Durable Immune Response against RSV 

  • Updated Clinical Plans to Develop and Initiate a Human Challenge Study in 2018

COPENHAGEN, Denmark, September 21, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced initial 6 month follow-up data from the Phase 2 trial of MVA-BN® RSV, a universal vaccine candidate designed to induce protective immune responses against both subtypes (A & B) of the respiratory syncytial virus (RSV). The randomized, placebo-controlled trial, evaluated the safety, tolerability and immunogenicity of the recombinant vaccine in 421 healthy adults aged 55 and older.

The subjects were enrolled into four active arms of the study, which examined the effects of both a high (5x108) and low (1x108) dose, administered as either one or two vaccinations (day 0, 28) and compared to a placebo arm. At 6 month follow up, a persistent antibody response against multiple RSV targets can still be observed. 

Also announced today are the Company's updated clinical plans for the RSV vaccine, which will now include a human challenge study. Anticipated to initiate recruitment in the second half of 2018 the placebo-controlled study will explore the protective effects of MVA-BN RSV. Bavarian Nordic intends to use evidence from the challenge study to assist in the planning and design of late phase RSV studies as well as demonstrating early evidence regarding efficacy of MVA-BN RSV in preventing disease in healthy volunteers subsequently exposed to live RSV.

Bavarian Nordic will partner with a global CRO to develop a novel and differentiated approach to the RSV challenge model. Previous attempts at RSV challenge studies have historically been seen as lacking in sufficient measurable outcomes, which may be associated with the relatively low virulence of the virus administered to volunteers. The CRO has developed a new primary isolate of RSV which, in infectivity assays, has demonstrated  a degree of virulence and pathogenicity more commonly associated with circulating, wild-type strains. This new model will potentially allow Bavarian Nordic to more accurately assess the protective benefits of its vaccine when confronted with a virulent RSV infection.

"We are very happy to report this data, once again demonstrating the durability of our vaccine for up to 6 months," said Paul Chaplin, President and CEO of Bavarian Nordic, "Announcing the development of a more virulent RSV human challenge model creates the potential to gain efficacy data of our RSV vaccine prior to initiating the pivotal Phase 3. The global CRO is an ideal partner and a leader in the field having previously been successful in developing a virulent influenza challenge model."

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE®, which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX®) and in Canada. Bavarian Nordic and its strategic partner Janssen are developing an Ebola vaccine regimen, and therapeutic vaccines for HPV, HBV and HIV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC®, which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic.

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contacts

Rolf Sass Sørensen

Vice President Investor Relations (EU)

Tel: +45 61 77 47 43

Seth Lewis

Vice President Investor Relations (US)

Tel: +1 978 341 5271

Company Announcement no. 27 / 2017

2017-27-en


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Bavarian Nordic A/S via Globenewswire

Vedhæftet fil: 817341.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
21 sep
BAVA
Det er ikke så svært at finde grunden. Rigtig ofte vinder hedgefondene på deres shorts. Nogle gange ..
9
21 sep
BAVA
Jeg havde en frygt for, at BAVA kunne møde modstand her ved 175, og det ser meget aktuelt ud. Ved si..
5
24 sep
BAVA
Hvis man tager CARs analyse fra i dag har de følgende sammensætning af pipelinens værdi:   SOTP of D..
4
24 sep
BAVA
Bavarian - hvad er deres pipeline værd .... kort før Prostvac resultatet blev annonceret med resulta..
4
21 sep
BAVA
Du har da ret i, at når Wace fonden for nyligt har øget i Bavarian, er det ikke sket til 250. Men je..
4
24 sep
BAVA
Carnegie har genoptaget dækning af Bavarian Nordic med anbefalingen køb og et kursmål på 245 kr. Det..
3
20 sep
BAVA
BAVARIAN NORDIC LEVERER KOPPEVACCINER TIL ENGLANDS BEREDSKAB I FORBINDELSE MED AKTUELLE TILFÆLDE AF ..
3
20 sep
BAVA
Det ser ud til den har nået bunden i denne omgang og kører modsat - gennemgangen på aktionærforening..
3
22 sep
BAVA
Det handler ikke om, at man absolut skal skrive jublende indlæg om Bavarian, naturligvis behøver man..
2
22 sep
BAVA
Hej Turin, Nu synes jeg, du er lige hurtig nok ude i din dom. Når jeg siger, jeg er totalt positi..
2

Widex hentede stor fremgang i 2017/18 - NY2

26-09-2018 09:58:19
Den privatejede danske høreapparatkoncern Widex kunne igen i regnskabsåret 2017/18 melde om fremgang i selskabets hovedtal.Omsætningen steg i regnskabsåret, der løb frem til udgangen af april, til 4466 mio. kr. fra 4346 mio. kr. i 2016/17.Det blev omsat til et normaliseret driftsresultat (EBITA) på 901 mio. kr. mod 790 mio. kr. året før.Dermed kan EBITA-marginen opgøres til 20,2 pct. mod 18,2 pct...

Aktier/tendens: Danske Bank igen i vælten på ventet grønt marked

26-09-2018 08:10:16
Det ledende danske aktieindeks, C25, kan onsdag fortsætte tirsdagens positive takter og lægge yderligere til, på en dag hvor Danske Bank endnu engang kan komme i fokus.Bankens aktiekurs steg tirsdag med 2,2 pct. til 170 kr., men banken måtte sent tirsdag eftermiddag se udsigterne for kreditvurderingen hos både Fitch og Standard & Poor's blive sænket til "negative".- De negative udsigter afspejler ..

Danske: Fitch sænker udsigter for kreditvurdering til "negative" - NY

25-09-2018 15:58:53
Fitch Ratings tager kreditvurderingen af Danske Bank op til fornyet overvejelse. Kreditvurderingsinstituttet sænker udsigterne til "negative" fra "stabile".I første omgang fastholder Fitch vurderingen "A". Men i lyset af hvidvasksagen er der mulighed for, at vurderingen af banken sættes ned.Det oplyser Fitch tirsdag.Den negative vurdering afspejler den usikkerhed, der er kommet omkring Danske Bank..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
MHI Vestas/dir: Vi er langt foran konkurrenterne med tocifret havmølle
2
Aktier/tendens: Danske Bank igen i vælten på ventet grønt marked
3
Tirsdagens aktier: Firkløver trak C25 i plus - Pandora faldt til bunds
4
Aktier/middag: Udenlandsk interesse for Pandora presser kursen op
5
Danske Bank/S&P: Sænker udsigter og den selvstædige kreditprofil -GENT

Relaterede aktiekurser

Bavarian Nordic A/S 171,90 -2,6% Fald i aktiekurs
Bavarian Nordic Ord Shs 171,90 -2,6% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Berlingske Media 2018  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. september 2018 15:28:32
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180919.1 - EUROWEB6 - 2018-09-26 15:28:32 - 2018-09-26 15:28:32 - 1 - Website: OKAY